20 November 2018
: Case report
Use of Ivermectin in Neurocysticercosis: A Case Report
Unusual setting of medical care, Rare disease, Educational Purpose (only if useful for a systematic review or synthesis)
Mohammed S. Samannodi1ABD*, Andrew Zhao2CDEF, Rodrigo Hasbun1ABCDOI: 10.12659/AJCR.911269
Am J Case Rep 2018; 19:1378-1381
Abstract
BACKGROUND: Neurocysticercosis is a Taenia solium infection which utilizes the tapeworm as a vector and humans as a definitive host and causes development of cystic lesions in the central nervous system. The current established medical therapy is albendazole with praziquantel as a secondary agent, but results can be mixed depending on each patient and their form of neurocysticercosis.
CASE REPORT: We present a case pertaining to a young female patient diagnosed with single parenchymal neurocysticercosis based on clinical and diagnostic findings. This case was unique in the sense that ivermectin, another antiparasitic agent, was used as monotherapy with significant improvement in the patient’s clinical presentation and radiological findings.
CONCLUSIONS: Despite current guidelines recommending use of albendazole with or without praziquantel for neurocysticercosis, our case (as well as 4 other cases documented in the recent past) suggest a possible use of ivermectin as potential therapy for neurocysticercosis. We recommend continued research regarding other cases of ivermectin use in similar patients and even comparison studies with albendazole with or without praziquantel in terms of efficacy and side effects in order to better treat this international endemic.
Keywords: albendazole, Ivermectin, Neurocysticercosis
SARS-CoV-2/COVID-19
11 August 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936496
09 August 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.937505
29 July 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.937105
08 July 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.937212
In Press
17 Aug 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936537
16 Aug 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.937511
16 Aug 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.937598
16 Aug 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936743
Most Viewed Current Articles
13 Jul 2022 : Case report
DOI :10.12659/AJCR.936441
Am J Case Rep 2022; 23:e936441
23 Feb 2022 : Case report
DOI :10.12659/AJCR.935250
Am J Case Rep 2022; 23:e935250
06 Dec 2021 : Case report
DOI :10.12659/AJCR.934406
Am J Case Rep 2021; 22:e934406
17 Feb 2022 : Case report
DOI :10.12659/AJCR.934399
Am J Case Rep 2022; 23:e934399